This website uses cookies. These cookies allow us to recognize, distinguish and count the number of visitors to our site, helping us to provide you with a good experience while browsing our website. Please check the box to acknowledge the use of cookies. To find out more about this, please see our privacy policy.
Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.
Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.
Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.
For all other inquiries please contact: info@interceptpharma.com
YOU ARE NOW LEAVING INTERCEPTMEDINFO.COM
Intercept does not control the content of this external site.
INTERCEPT MEDICAL INFORMATION
This site is intended for healthcare professionals from the U.S. only. Please select the option that best describes you.
Medical Information Request
Thank you for submitting your medical inquiry. In the event that you have any questions regarding your inquiry, please contact medinfo@interceptpharma.com.